未登录

H

Hansell H. Stedman

University of Pennsylvania

H指数:31

被引数:5,767

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Optimal murine CD4+ T cell priming by mRNA-lipid nanoparticle vaccines requires endogenous antigen processing

通过mRNA-脂质纳米颗粒疫苗引发的最佳鼠CD4 T细胞需要内源性抗原加工

Nature Communications

IF15.7

2026-01-160

OAAI

AAV-microutrophin gene therapy confers durable cardioprotection against pharmacologic and exercise-induced injury in the mdx mouse

AAV-microutrophin基因治疗为mdx小鼠提供了对药理学和运动诱导损伤的持续性心脏保护。

Molecular Therapy

IF12

2025-07-160

PRE

Challenges at the Crossroads: Myopathy Trials in 2020 Hindsight

MOLECULAR THERAPY

IF12

2021-02-014

OAAI

Broader Implications of Progressive Liver Dysfunction and Lethal Sepsis in Two Boys following Systemic High-Dose AAV

MOLECULAR THERAPY

IF12

2020-08-0163

OAAI

Non-immunogenic utrophin gene therapy for the treatment of muscular dystrophy animal models

NATURE MEDICINE

IF50

2019-10-0762

OAAI

Suite of clinically relevant functional assays to address therapeutic efficacy and disease mechanism in the dystrophic mdx mouse

JOURNAL OF APPLIED PHYSIOLOGY

IF3.3

2017-03-014

OA

AAV9-Utrophin Prevents Myonecrosis in Dystrophic Mice and Dogs without Immunosuppression

MOLECULAR THERAPY

IF12

2016-05-010

OAAI

AAV9-Utrophin Restores Muscle Function in Dystrophic Mice

MOLECULAR THERAPY

IF12

2016-05-010

OAAI

Prevention of Muscular Dystrophy by an AAV Vector Encoding a Nonimmunogenic Protein Based on the Evolution of Utrophin and Dystrophin

MOLECULAR THERAPY

IF12

2016-05-010

OAAI

Clinico-Pathological Correlation in the Earliest Stages of Muscular Dystrophy Suggests Sensitive Physiological Parameters as Novel Primary Endpoints for Systemic Gene Therapy

MOLECULAR THERAPY

IF12

2016-05-010

OAAI

A Reproducible and Reliable Non-Invasive Approach to Assess the Efficacy of Gene Therapy in mdx Mice with Relevance to Clinical Trials

MOLECULAR THERAPY

IF12

2016-05-010

OAAI

Hypersensitivity of MYH16 Fibers (M Fibers) to Myodegeneration in Canine Muscular Dystrophy

MOLECULAR THERAPY

IF12

2016-05-010

OAAI

Muscular Dystrophy Genes and the Early Metazoan Transition from Dynein- to Myosin-Powered Locomotion

MOLECULAR THERAPY

IF12

2016-05-010

OAAI

Concerted Evolution of Pseudogenes Facilitated Contiguous Deletion of the Canine Dystrophin and TMEM47 Genes by Homologous Recombination

MOLECULAR THERAPY

IF12

2016-05-010

OAAI

Diaphragm remodeling and compensatory respiratory mechanics in a canine model of Duchenne muscular dystrophy

JOURNAL OF APPLIED PHYSIOLOGY

IF3.3

2014-04-0133

OAAI

Cardiac Surgical Delivery of the Sarcoplasmic Reticulum Calcium ATPase Rescues Myocytes in Ischemic Heart Failure

ANNALS OF THORACIC SURGERY

IF3.9

2013-08-0124

OAAI

Signs of Progress in Gene Therapy for Muscular Dystrophy Also Warrant Caution

MOLECULAR THERAPY

IF12

2012-02-010

OAAI

A Pharmacokinetic Analysis of Molecular Cardiac Surgery With Recirculation Mediated Delivery of βARKct Gene Therapy: Developing a Quantitative Definition of the Therapeutic Window

JOURNAL OF CARDIAC FAILURE

IF8.2

2011-08-0110

OAAI

Safety of AAV Factor IX Peripheral Transvenular Gene Delivery to Muscle in Hemophilia B Dogs

MOLECULAR THERAPY

IF12

2010-07-0168

OAAI

Safety and efficacy of regional intravenous (RI) versus intramuscular (IM) delivery of rAAV1 and rAAV8 to nonhuman primate skeletal muscle

MOLECULAR THERAPY

IF12

2008-07-0190

OA